Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
03 Maio 2021 - 07:45AM
Business Wire
- Standalone company positioned to deliver low to mid-single
digit revenue growth off 2021 base
- Future growth opportunities include Women’s Health and
Biosimilars businesses; Established Brands portfolio expected to
provide significant cash flow to invest in new opportunities, with
modest future LOE risk after 2021
- Organon will have a diverse product portfolio with no product
representing more than 11% of total revenue, and an expansive
global geographic footprint with nearly 80% of revenue generated
outside the U.S.
- Experienced management team and majority-female Board of
Directors focused on the vision to create a better and healthier
every day for every woman around the globe
- Organon will begin regular way trading on the New York Stock
Exchange under ticker symbol “OGN” on June 3
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today will host Organon management at a meeting with the
investment community. Management will detail plans for how Organon
is expected to drive sustainable growth and shareholder value as a
standalone company.
“The spinoff of Organon will help Merck become a leaner, more
focused and agile company with stronger growth, and will enable
significant operating efficiencies. Organon, as a standalone
company, will be better positioned to realize its potential and to
have a meaningful impact, particularly in women’s health”, said Rob
Davis, president, Merck. “We believe this transaction will create
value for the patients both companies serve and for Merck
shareholders.”
At launch, Organon’s portfolio will consist of more than 60
medicines and products across its three core franchises: Women’s
Health, Biosimilars and Established Brands.
“On June 3rd, Organon will launch as a new company, with solid
growth opportunities and the ability to make an impact in women’s
health,” said Kevin Ali, Organon’s chief executive officer. “Our
day one portfolio consists of many well-known products that were
once core to Merck’s business but have since strategically received
limited resources and investment. These are important medicines
that we believe will be responsive to commercial investment, and
with renewed management focus, we expect the portfolio to generate
low to mid-single organic revenue growth off of a 2021 base.
Additionally, as the only company of our size to be focused on
women’s health, we have a significant opportunity to do more to
support women and their health, and the time is right to bring
forward more options for patients and healthcare providers.”
During the event, members of Organon’s leadership team will
outline the company’s strategic priorities to generate value for
patients and shareholders. These include:
- Developing a new commercial strategy and roadmap for
sustainable growth. Organon has a strong and balanced
foundation with a diverse portfolio of impactful brands built on a
broad geographic footprint. With management focus and renewed
investment, the company intends to capitalize on the growth
potential of the existing Women’s Health and Biosimilars
portfolios, while optimizing the well-known brands and associated
cash flows of the Established Brands business. Organon will launch
with a large commercial footprint with a direct sales presence in
58 markets, while supplying products to over 140 markets. The
company has also begun to execute on its vision of becoming a
leader in women’s health, with the recently announced proposed
acquisition of Alydia Health.
- Driving leadership in women’s health. Organon has a
scaled portfolio of contraceptive and fertility brands, anchored by
market exclusivity for NEXPLANON (etonogestrel implant), that
delivered approximately $1.6 billion in global sales in 2020 and
has long-term growth potential. Organon will also broaden its
definition of women’s health beyond contraception and fertility to
address conditions that are unique to women as well as health
issues that disproportionately affect women, placing Organon in an
addressable market of more than $60 billion by 2026.
- Executing on the commercialization of Biosimilars.
Organon will be in a strong position with the products in its
current portfolio through its long-standing collaboration with
Samsung Bioepis. Growth drivers in Organon’s Biosimilars portfolio
are expected to include the continued success of RENFLEXIS
(infliximab-abda) in the U.S., the launch of AYBINTIO (bevacizumab)
in the EU and HADLIMA (adalimumab-bwwd) in Canada, as well as the
anticipated launch of HADLIMA in the U.S. in 2023.
- Leveraging the Established Brands portfolio for steady cash
flow. The Established Brands business consists of 49 products
across a range of therapeutic areas, including respiratory,
cardiovascular, dermatology and non-opioid pain, and delivered $4.5
billion of revenue in 2020. This portfolio includes brands beyond
their patent loss in most markets, with only modest remaining LOE
exposure beyond 2021. The company will look to capitalize on these
well-known and recognizable brands in international markets by
selectively increasing commercial spend in areas that have the
potential to offer solid returns.
- Developing a new R&D approach with women at the
center. Organon will look across academic centers, as well as
early and established companies, to find promising drugs,
diagnostics and devices to develop through its global capabilities
in clinical development and patient safety, regulatory and medical
affairs. Its R&D philosophy is to build a business around
patient needs, advancing healthcare options for women that enable
them to live their best lives every day.
2021 Investor Day Presenters Investor Day will feature
presentations from the following Merck and Organon executives in
order of their appearance:
- Rob Davis, President, Merck
- Kevin Ali, Chief Executive Officer, Organon
- Susanne Fiedler, Chief Commercial Officer, Organon
- Simon Holland, Women’s Health, Commercial Lead,
Organon
- Elisabeth Weis, Fertility, Commercial Lead, Organon
- Joe Azzinaro, Biosimilars, Commercial Lead, Organon
- Ger Brennan, Established Brands, Commercial Lead,
Organon
- Sandy Milligan, Head of Research & Development,
Organon
- Matthew Walsh, Chief Financial Officer, Organon
The full biographies of the speakers can be found at
www.merck.com/events/organon-co-investor-day.
Webcast Details Merck invites shareholders, the
investment community, the media and the general public to tune into
the webcast of the Investor Day event today from 10:00 am to 12:15
pm EDT. To register for the webcast and view related materials,
including presentations and speaker biographies, please visit the
website at www.merck.com/events/organon-co-investor-day or
listen-in to the audio-only teleconference with the opportunity to
ask questions by dialing 1-844-340-4759 or internationally at
1-412-717-9615. A replay and transcript will be available shortly
after the completion of the live webcast.
About Merck For 130 years, Merck, known as MSD outside of
the United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve
lives. We demonstrate our commitment to patients and population
health by increasing access to health care through far-reaching
policies, programs and partnerships. Today, Merck continues to be
at the forefront of research to prevent and treat diseases that
threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases – as we aspire
to be the premier research-intensive biopharmaceutical company in
the world. For more information, visit www.merck.com and connect
with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About Organon Organon will be a global healthcare company
formed through a spinoff from Merck to focus on improving the
health of women throughout their lives. It will have a portfolio of
more than 60 medicines and products that help address a spectrum of
conditions women face. Led by the reproductive health portfolio
coupled with an expanding biosimilars business and stable franchise
of established medicines, Organon’s products are expected to
produce strong cash flows that will support investments in future
growth opportunities in women’s health. In addition, Organon will
pursue opportunities to collaborate with biopharmaceutical
innovators looking to commercialize their products by leveraging
its scale and presence in fast-growing international markets.
Organon is expected to have a global footprint with significant
scale and geographic reach, world-class commercial capabilities,
and Organon is expected to have a global footprint with significant
scale and geographic reach, world-class commercial capabilities,
and approximately 10,000 employees with headquarters located in
Jersey City, New Jersey.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA This news release of Merck & Co.,
Inc., Kenilworth, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Examples of forward-looking statements include statements
with respect to the company’s plans to spinoff certain of its
businesses into an independent company, the timing and structure of
such spinoff, the characteristics of the business to be separated,
the expected benefits of the spinoff to the company and the
expected effect on the company’s dividends, estimates of future
Organon revenues or other results of operations, the timing of any
product launches by Organon and estimates of the markets in which
Organon will operate. These statements are based upon the current
beliefs and expectations of the company’s management and are
subject to significant risks and uncertainties. There can be no
guarantees with respect to whether the proposed spinoff will be
completed on the proposed timetable or at all. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to,
uncertainties as to the timing of the proposed spinoff;
uncertainties as to the status of any required regulatory
approvals; the possibility that various conditions to the
consummation of the spinoff may not be satisfied; the effects of
disruption from the transactions contemplated in connection with
the spinoff; general industry conditions and competition; general
economic factors, including interest rate and currency exchange
rate fluctuations; the impact of pharmaceutical industry regulation
and health care legislation in the United States and
internationally; the impact of the global outbreak of novel
coronavirus disease (COVID-19); global trends toward health care
cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; the company’s
ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the company’s patents and other protections for
innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K, Organon’s Registration Statement on
Form 10 (File No. 001-40235) and the company’s other filings with
the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210503005228/en/
Media Contacts:
Patrick Ryan (908) 740-1038
Jess Fine (908) 740-1707
Investor Contacts:
Peter Dannenbaum (908) 740-1037
Courtney Ronaldo (908) 740-6132
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024